Adult diffuse gliomas produce mRNA transcripts encoding EGFR isoforms lacking a tyrosine kinase domain

Guillaudeau,Angélique; Durand,Karine; Rabinovitch-Chable,Hélène; Pommepuy,Isabelle; Mesturoux,Laura; Robert,Sandrine; Chaunavel,Alain; Moreau,Jean-Jacques; Labrousse,François

doi:10.3892/ijo.2011.1287

Adult diffuse gliomas produce mRNA transcripts encoding EGFR isoforms lacking a tyrosine kinase domain

Authors:
- Angélique Guillaudeau
- Karine Durand
- Hélène Rabinovitch-Chable
- Isabelle Pommepuy
- Laura Mesturoux
- Sandrine Robert
- Alain Chaunavel
- Jean-Jacques Moreau
- François Labrousse
View Affiliations

Affiliations: Department of Pathology, Dupuytren University Hospital, 2 Avenue Martin Luther King, F-87042 Limoges, France
Published online on: December 8, 2011 https://doi.org/10.3892/ijo.2011.1287
Pages: 1142-1152

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The epidermal growth factor receptor (EGFR) gene encodes four alternatively spliced mRNA, variants 1, 2, 3 and 4, respectively, encoding the whole isoform a (EGFR) and truncated isoforms b, c and d, all of which lack the receptor's intracellular domain. In addition, a mutant EGFRvIII differs from isoform a in a truncated extracellular domain. The expression pattern of these isoforms is unknown in adult diffuse gliomas. Thus, we investigated in 47 cases: i) EGFR protein expression by immunohistochemistry using an extracellular domain-recognizing antibody (Ext-Ab) and an intracellular domain specific one (Int-Ab), ii) mRNA expression of EGFRv1, -v2, -v3, -v4 and -vIII by RT-PCR and iii) EGFR amplification by fluorescent in situ hybridization. The relation of these data with histological criteria and patient outcome was studied. The immunostaining was stronger with the Ext-Ab than with the Int-Ab. EGFRv1, -v2, -v3 and -v4 mRNA expression were highly correlated. They were expressed in all tumors, with highest levels in glioblastomas. EGFRv1 strong levels and the presence of vIII mRNAs were more closely associated with Int-Ab staining. EGFR gene amplification concerned only glioblastomas and was associated with the presence of EGFRvIII and high levels of EGFRv2, -v3 and -v4 transcripts. A pejorative outcome was associated with: histology (glioblastomas), EGFR amplification, strong Int-Ab labeling and high levels of variant mRNAs. Our results indicated that the full-length EGFR and mutant EGFRvIII are not the sole EGFR isoform expressed in diffuse gliomas. This could explain discordant immunohistochemical results reported in the literature and may have therapeutic implications.

View Figures

View References

1	Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, Scheithauer BW and Kleihues P: The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 114:97–109. 2007. View Article : Google Scholar : PubMed/NCBI
2	Krex D, Klink B, Hartmann C, von Deimling A, Pietsch T, Simon M, Sabel M, Steinbach JP, Heese O, Reifenberger G, Weller M and Schackert G: Long-term survival with glioblastoma multiforme. Brain. 130:2596–2606. 2007. View Article : Google Scholar : PubMed/NCBI
3	Andersson U, Guo D, Malmer B, Bergenheim AT, Brannstrom T, Hedman H and Henriksson R: Epidermal growth factor receptor family (EGFR, ErbB2-4) in gliomas and meningiomas. Acta Neuropathol. 108:135–142. 2004. View Article : Google Scholar : PubMed/NCBI
4	Bredel M, Pollack IF, Hamilton RL and James CD: Epidermal growth factor receptor expression and gene amplification in high-grade non-brainstem gliomas of childhood. Clin Cancer Res. 5:1786–1792. 1999.PubMed/NCBI
5	McLendon RE, Turner K, Perkinson K and Rich J: Second messenger systems in human gliomas. Arch Pathol Lab Med. 131:1585–1590. 2007.PubMed/NCBI
6	Potti A, Forseen SE, Koka VK, Pervez H, Koch M, Fraiman G, Mehdi SA and Levitt R: Determination of HER-2/neu overexpression and clinical predictors of survival in a cohort of 347 patients with primary malignant brain tumors. Cancer Invest. 22:537–544. 2004. View Article : Google Scholar : PubMed/NCBI
7	Schlegel J, Stumm G, Brandle K, Merdes A, Mechtersheimer G, Hynes NE and Kiessling M: Amplification and differential expression of members of the erbB-gene family in human glioblastoma. J Neurooncol. 22:201–207. 1994. View Article : Google Scholar : PubMed/NCBI
8	Tabori U, Rienstein S, Dromi Y, Leider-Trejo L, Constantini S, Burstein Y, Dvir R, Amariglio N, Toren A, Rechavi G, Izraeli S and Aviram A: Epidermal growth factor receptor gene amplification and expression in disseminated pediatric low-grade gliomas. J Neurosurg. 103:357–361. 2005.PubMed/NCBI
9	Gil-Benso R, Lopez-Gines C, Benito R, Lopez-Guerrero JA, Callaghan RC, Pellin A, Roldan P and Cerda-Nicolas M: Concurrent EGFR amplification and TP-53 mutation in glioblastomas. Clin Neuropathol. 26:224–231. 2007. View Article : Google Scholar : PubMed/NCBI
10	Nakamura JL: The epidermal growth factor receptor in malignant gliomas: pathogenesis and therapeutic implications. Expert Opin Ther Targets. 11:463–472. 2007. View Article : Google Scholar : PubMed/NCBI
11	Okada Y, Ohno C, Ueki K, Ogino M, Kawamoto S and Kim P: Comparison of numerical change of epidermal growth factor receptor gene among pre- and postradiation glioma, and gliosis, and its clinical use. Brain Tumor Pathol. 24:15–18. 2007. View Article : Google Scholar : PubMed/NCBI
12	Schober R, Bilzer T, Waha A, et al: The epidermal growth factor receptor in glioblastoma: genomic amplification, protein expression, and patient survival data in a therapeutic trial. Clin Neuropathol. 14:169–174. 1995.
13	Shinojima N, Tada K, Shiraishi S, Kamiryo T, Kochi M, Nakamura H, Makino K, Saya H, Hirano H, Kuratsu J, Oka K, Ishimaru Y and Ushio Y: Prognostic value of epidermal growth factor receptor in patients with glioblastoma multiforme. Cancer Res. 63:6962–6970. 2003.PubMed/NCBI
14	Torp SH, Helseth E, Dalen A and Unsgaard G: Epidermal growth factor receptor expression in human gliomas. Cancer Immunol Immunother. 33:61–64. 1991. View Article : Google Scholar : PubMed/NCBI
15	Torp SH, Helseth E, Ryan L, Stolan S, Dalen A and Unsgaard G: Amplification of the epidermal growth factor receptor gene in human gliomas. Anticancer Res. 11:2095–2098. 1991.PubMed/NCBI
16	Gan HK, Kaye AH and Luwor RB: The EGFRvIII variant in glioblastoma multiforme. J Clin Neurosci. 16:748–754. 2009. View Article : Google Scholar : PubMed/NCBI
17	Lal A, Glazer CA, Martinson HM, Friedman HS, Archer GE, Sampson JH and Riggins GJ: Mutant epidermal growth factor receptor up-regulates molecular effectors of tumor invasion. Cancer Res. 62:3335–3339. 2002.PubMed/NCBI
18	Sampson JH, Heimberger AB, Archer GE, Aldape KD, Friedman AH, Friedman HS, Gilbert MR, Herndon JE II, McLendon RE, Mitchell DA, Reardon DA, Sawaya R, Schmittling RJ, Shi W, Vredenburgh JJ and Bigner DD: Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma. J Clin Oncol. 28:4722–4729. 2010. View Article : Google Scholar
19	Maihle NJ, Baron AT, Barrette BA, Boardman CH, Christensen TA, Cora EM, Faupel-Badger JM, Greenwood T, Juneja SC, Lafky JM, Lee H, Reiter JL and Podratz KC: EGF/ErbB receptor family in ovarian cancer. Cancer Treat Res. 107:247–258. 2002.PubMed/NCBI
20	Reiter JL and Maihle NJ: Characterization and expression of novel 60-kDa and 110-kDa EGFR isoforms in human placenta. Ann NY Acad Sci. 995:39–47. 2003. View Article : Google Scholar : PubMed/NCBI
21	Reiter JL, Threadgill DW, Eley GD, Strunk KE, Danielsen AJ, Sinclair CS, Pearsall RS, Green PJ, Yee D, Lampland AL, Balasubramaniam S, Crossley TD, Magnuson TR, James CD and Maihle NJ: Comparative genomic sequence analysis and isolation of human and mouse alternative EGFR transcripts encoding truncated receptor isoforms. Genomics. 71:1–20. 2001. View Article : Google Scholar
22	Flickinger TW, Maihle NJ and Kung HJ: An alternatively processed mRNA from the avian c-erbB gene encodes a soluble, truncated form of the receptor that can block ligand-dependent transformation. Mol Cell Biol. 12:883–893. 1992.PubMed/NCBI
23	Weber W, Gill GN and Spiess J: Production of an epidermal growth factor receptor-related protein. Science. 224:294–297. 1984. View Article : Google Scholar : PubMed/NCBI
24	Cadena DL and Gill GN: Expression and purification of the epidermal growth factor receptor extracellular domain utilizing a polycistronic expression system. Protein Expr Purif. 4:177–186. 1993. View Article : Google Scholar
25	Greenfield C, Hiles I, Waterfield MD, Federwisch M, Wollmer A, Blundell TL and McDonald N: Epidermal growth factor binding induces a conformational change in the external domain of its receptor. EMBO J. 8:4115–4123. 1989.PubMed/NCBI
26	Basu A, Raghunath M, Bishayee S and Das M: Inhibition of tyrosine kinase activity of the epidermal growth factor (EGF) receptor by a truncated receptor form that binds to EGF: role for interreceptor interaction in kinase regulation. Mol Cell Biol. 9:671–677. 1989.PubMed/NCBI
27	Hirsch FR, Varella-Garcia M, Bunn PA Jr, Di Maria MV, Veve R, Bremmes RM, Baron AE, Zeng C and Franklin WA: Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis. J Clin Oncol. 21:3798–3807. 2003. View Article : Google Scholar : PubMed/NCBI
28	Guillaudeau A, Durand K, Pommepuy I, Robert S, Chaunavel A, Lacorre S, De Armas R, Bourtoumieux S, El Demery M, Moreau JJ and Labrousse F: Determination of EGFR status in gliomas: usefulness of immunohistochemistry and fluorescent in situ hybridization. Appl Immunohistochem Mol Morphol. 17:220–226. 2009. View Article : Google Scholar : PubMed/NCBI
29	Pfaffl MW: A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res. 29:e452001. View Article : Google Scholar : PubMed/NCBI
30	Korshunov A, Sycheva R and Golanov A: Molecular stratification of diagnostically challenging high-grade gliomas composed of small cells: the utility of fluorescence in situ hybridization. Clin Cancer Res. 10:7820–7826. 2004. View Article : Google Scholar : PubMed/NCBI
31	Marks RA, Zhang S, Montironi R, McCarthy RP, MacLennan GT, Lopez-Beltran A, Jiang Z, Zhou H, Zheng S, Davidson DD, Baldridge LA and Cheng L: Epidermal growth factor receptor (EGFR) expression in prostatic adenocarcinoma after hormonal therapy: a fluorescence in situ hybridization and immunohistochemical analysis. Prostate. 68:919–923. 2008. View Article : Google Scholar
32	Durand K, Guillaudeau A, Pommepuy I, Mesturoux L, Chaunavel A, Gadeaud E, Porcheron M, Moreau JJ and Labrousse F: Alpha-internexin expression in gliomas: relationship with histological type and 1p, 19q, 10p and 10q status. J Clin Pathol. 64:793–801. 2011. View Article : Google Scholar : PubMed/NCBI
33	Durand KS, Guillaudeau A, Weinbreck N, De Armas R, Robert S, Chaunavel A, Pommepuy I, Bourthoumieu S, Caire F, Sturtz FG and Labrousse FJ: 1p19q LOH patterns and expression of p53 and Olig2 in gliomas: relation with histological types and prognosis. Mod Pathol. 23:619–628. 2010. View Article : Google Scholar : PubMed/NCBI
34	Hirose T, Ishizawa K and Shimada S: Utility of in situ demonstration of 1p loss and p53 overexpression in pathologic diagnosis of oligodendroglial tumors. Neuropathology. 30:586–596. 2010. View Article : Google Scholar : PubMed/NCBI
35	Ligon KL, Alberta JA, Kho AT, Weiss J, Kwaan MR, Nutt CL, Louis DN, Stiles CD and Rowitch DH: The oligodendroglial lineage marker OLIG2 is universally expressed in diffuse gliomas. J Neuropathol Exp Neurol. 63:499–509. 2004.PubMed/NCBI
36	Okada M, Yano H, Hirose Y, Nakayama N, Ohe N, Shinoda J and Iwama T: Olig2 is useful in the differential diagnosis of oligodendrogliomas and extraventricular neurocytomas. Brain Tumor Pathol. 28:157–161. 2011. View Article : Google Scholar : PubMed/NCBI
37	Coulibaly B, Nanni I, Quilichini B, Gaudart J, Metellus P, Fina F, Boucard C, Chinot O, Ouafik L and Figarella-Branger D: Epidermal growth factor receptor in glioblastomas: correlation between gene copy number and protein expression. Hum Pathol. 41:815–823. 2010. View Article : Google Scholar : PubMed/NCBI
38	Ilekis JV, Stark BC and Scoccia B: Possible role of variant RNA transcripts in the regulation of epidermal growth factor receptor expression in human placenta. Mol Reprod Dev. 41:149–156. 1995. View Article : Google Scholar : PubMed/NCBI
39	Voelzke WR, Petty WJ and Lesser GJ: Targeting the epidermal growth factor receptor in high-grade astrocytomas. Curr Treat Options Oncol. 9:23–31. 2008. View Article : Google Scholar : PubMed/NCBI
40	Albitar L, Pickett G, Morgan M, Wilken JA, Maihle NJ and Leslie KK: EGFR isoforms and gene regulation in human endometrial cancer cells. Mol Cancer. 9:1662010. View Article : Google Scholar : PubMed/NCBI
41	Lafky JM, Wilken JA, Baron AT and Maihle NJ: Clinical implications of the ErbB/epidermal growth factor (EGF) receptor family and its ligands in ovarian cancer. Biochim Biophys Acta. 1785:232–265. 2008.PubMed/NCBI
42	Shibata MA, Ambati J, Shibata E, Albuquerque RJ, Morimoto J, Ito Y and Otsuki Y: The endogenous soluble VEGF receptor-2 isoform suppresses lymph node metastasis in a mouse immunocompetent mammary cancer model. BMC Med. 8:692010. View Article : Google Scholar : PubMed/NCBI